An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

Phase 3 Completed 217 enrolled UCB Pharma

NaSingle-groupOpen-labelTreatment

Summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.

Timeline

Start: 2002-06
Primary completion: 2008-11
Completion: 2008-11

Publications

Results Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun;18(5):488-93. doi: 10.1016/j.parkreldis.2012.01.008. Epub 2012 Feb 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotigotine	Unknown	2 mg	Other
Subject	Rotigotine	Unknown	4 mg	Other
Subject	Rotigotine	Unknown	6 mg	Other
Subject	Rotigotine	Unknown	8 mg	Other
Subject	Rotigotine	Unknown	16 mg	Other

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

Summary

Timeline

Publications

Drugs

Indications